The AIDS Vaccine 2012 Conference Abstract Book can be found at the following link: http://vaccineenterprise.org/conference/2012/sites/default/files/AV12%20Abstract_WebFinal.pdf
Webcasts of the conference sessions can be found at the following link: http://aidsvac.capitalreach.com/
The unique GeoVax two-component vaccine regimen, a recombinant DNA and a recombinant modified vaccinia Ankara (MVA), is designed to stimulate both anti-HIV T cell and anti-HIV antibody immune responses. The GeoVax DNA and MVA vaccines are used in a prime/boost protocol in which priming is done with the DNA component and boosting with the MVA component. Both the DNA and MVA components express the three major proteins of the AIDS virus: Gag, Pol, and Env, and produce noninfectious virus-like-particles. Uniquely, the GeoVax vaccines express virus-like particles that display the trimeric membrane bound form of the HIV-1 envelope glycoprotein (Env). In GeoVax's second-generation vaccine regimen, the DNA prime co-expresses GM-CSF with the virus-like particles, delivering a normal human protein that stimulates immune responses to the site of vaccination. All preventive Phase 1 human clinical trials conducted to date have tested various combinations and doses of our DNA and MVA vaccines for their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as for the safety of the vaccines.
AIDS is an epidemic that can affect anyone, regardless of race, gender, age or sexual orientation. 33 million people are currently infected globally; it is estimated that there will be 2.5 million new infections this year. Since the beginning of the epidemic, more than a million people in the U.S. have contracted the virus. Every 9 1/2 minutes, someone in the U.S. is infected with AIDS. Globally, HIV is the top killer among women of reproductive age. HIV is a worldwide disease with different subtypes (or clades) of the virus predominating in different regions of the world. Clade B is the predominant subtype in North America. Globally, most infections involve subtypes AG, B and C. GeoVax vaccines are currently designed to function against clade B.
For more information, please visit www.geovax.com.
About the HVTN
The HVTN is the largest worldwide clinical trials network dedicated to the development and testing of preventive HIV/AIDS vaccines. The HVTN is an international collaboration that conducts all phases of clinical trials, from evaluating experimental vaccines for safety and the ability to stimulate immune responses, to testing vaccine efficacy. Support for the HVTN comes from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH). The Network's HIV Vaccine Trial Units are located at leading research institutions in 27 cities on four continents. The Network's headquarters are at the Fred Hutchinson Cancer Research Center in Seattle, Washington.
Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: HVTN will commence, complete enrollment, and generate data regarding GeoVax vaccine clinical trials as and when expected, GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective, less costly, or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.
Most Popular Stories
- Nelson Mandela Dies After Momentous Life
- Twitter Names Woman to Board
- NSA Tracks 5 Billion Cellphone Records a Day
- Nelson Mandela Dead at 95
- Pope Francis Says He'll Fight Child Sex Abuse
- Yemen Attack Kills 52
- Fast-Food Workers Want $15 an Hour
- W.H. Corrects Itself on Unclegate
- Roybal-Allard Tours Gordon Brush Plant
- Aspen Contracting Adding 300 Jobs